Abstract:Metformin and sulphonylureas are the most commonly used first-line anti-diabetic agents. However, medical practice guidelines and clinical experience caution against using these drugs in severe diabetic kidney disease. Consequently, the choice of anti-diabetic medicine in various stages of diabetic nephropathy should balance the benefits and risks to the patient. We aim to synthesize available evidence on the effectiveness and safety of metformin concerning sulfonylureas in patients with diabetic renal disease… Show more
“…Drug use for hypertension and diabetes may affect renal function deterioration, such as renin angiotensin aldosterone system inhibitors and sulfonylureas. 4,5 However, the drug use for these comorbidities were not assessed, which might have affected the results.…”
LINKED CONTENTThis article is linked to Hong et al papers. To view these articles, visit https://doi.org/10.1111/apt.17819 and https://doi.org/10.1111/apt.17937
“…Drug use for hypertension and diabetes may affect renal function deterioration, such as renin angiotensin aldosterone system inhibitors and sulfonylureas. 4,5 However, the drug use for these comorbidities were not assessed, which might have affected the results.…”
LINKED CONTENTThis article is linked to Hong et al papers. To view these articles, visit https://doi.org/10.1111/apt.17819 and https://doi.org/10.1111/apt.17937
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.